Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 8 5 W ELECTROLYTES.
AMINOSYN II 8.5% W/ELECTROLYTES vs TRAVASOL 8.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Travasol 8.5% with Electrolytes is a parenteral nutrition solution providing amino acids for protein synthesis, electrolytes for maintenance of acid-base balance and osmotic pressure, and calories to prevent protein catabolism and promote anabolism.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
Intravenous infusion via central vein: 500 mL to 2000 mL per day, infused at a rate not exceeding 0.2 g/kg/hour of amino acids. Dosing individualized based on caloric and protein requirements.
None Documented
None Documented
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Variable; amino acids have rapid distribution (minutes) and metabolic elimination (half-life ~1-2 hours for most). Clinical context: continuous infusion maintains steady state; half-life not typically used for dosing but reflects rapid clearance.
Renal >90% (as amino acids and metabolites); fecal <5%
Components are eliminated via metabolic pathways (e.g., amino acids undergo deamination, protein synthesis) and renal excretion of waste products (urea, creatinine). 100% of nitrogenous waste is renally excreted; electrolytes are excreted renally proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution